Renibus Therapeutics, a Southlake, TX-based clinical-stage biotech company, completed a $15m extension as part of its Series A financing, closing the round at $35m.
The round was led by family offices specializing in biotech investments.
Led by newly appointed CEO Frank Stonebanks with Co-Founder and former CEO Al Guillem transitioning to Executive Chairman of the Board, Renibus is a clinical-stage biotech company dedicated to advancing the cardiorenal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company’s portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, and RBT-3 for treatment of iron deficiency anemia and platinum-based kidney toxicity.
The company intends to use the funds to advance its pipeline, including its lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a cardiac surgery setting. RBT-2 is in development for the treatment of chronic kidney disease (CKD) and is scheduled to begin Phase I later this year. RBT-3 may commence Phase III development in Q3 2022 to treat iron deficient anemia, with a differentiated product profile than the current standard of care.
FinSMEs
21/02/2022